BioTek Receives Extraordinary New Product Line Award from Fisher
News Mar 04, 2014
BioTek Instruments, Inc. has received Thermo Fisher Scientific's "Extraordinary New Product Line" award for their Cytation 3 Cell Imaging Multi-Mode Reader.
The award was presented at the Fisher Scientific North America Sales Meeting, held February 24-26, 2014 in Denver, Colorado.
Cytation 3 was recognized by Fisher Scientific's product management team for its innovative technology and successful sales performance.
"We're proud to have Fisher Scientific as a strong partner, and honored to receive this award," noted Gary Barush, Director of Marketing and Sales at BioTek Instruments. "Together, and with Cytation 3's combination of cellular imaging and multi-mode microplate detection, we can continue to provide unique workflow solutions to any laboratory."
BioTek's patent pending Cytation™ 3 Cell Imaging Multi-Mode Reader combines automated digital fluorescence microscopy and conventional microplate detection in a modular and upgradable platform.
This allows for quantitative and phenotypic cellular analyses, and especially for live cell assays where Cytation 3's temperature control and available gas control module support the ideal environment to grow, image, count and further analyze cells in microplates and other sample vessels.
Cytation 3 is the recipient of two additional awards since its launch: MipTec New Product Innovation Award and the SelectScience "Scientists' Choice Award for Best Drug Discovery Product" Award. It is also a finalist in the 2014 Edison Awards® competition.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018